TW202308991A - 三苯化合物之固體形式 - Google Patents

三苯化合物之固體形式 Download PDF

Info

Publication number
TW202308991A
TW202308991A TW111117524A TW111117524A TW202308991A TW 202308991 A TW202308991 A TW 202308991A TW 111117524 A TW111117524 A TW 111117524A TW 111117524 A TW111117524 A TW 111117524A TW 202308991 A TW202308991 A TW 202308991A
Authority
TW
Taiwan
Prior art keywords
compound
crystalline form
cancer
solvent
diffraction pattern
Prior art date
Application number
TW111117524A
Other languages
English (en)
Chinese (zh)
Inventor
尼布 大法
馬修 強森
蘇瑞西 曼泰堤
潔瑪 瑞恩德
Original Assignee
美商亞士德製藥公司
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商亞士德製藥公司, 日商大鵬藥品工業股份有限公司 filed Critical 美商亞士德製藥公司
Publication of TW202308991A publication Critical patent/TW202308991A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
TW111117524A 2021-05-11 2022-05-10 三苯化合物之固體形式 TW202308991A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187125P 2021-05-11 2021-05-11
US63/187,125 2021-05-11

Publications (1)

Publication Number Publication Date
TW202308991A true TW202308991A (zh) 2023-03-01

Family

ID=81854861

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111117524A TW202308991A (zh) 2021-05-11 2022-05-10 三苯化合物之固體形式

Country Status (6)

Country Link
US (1) US20240228438A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337638A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518429A (cg-RX-API-DMAC7.html)
CN (1) CN117769540A (cg-RX-API-DMAC7.html)
TW (1) TW202308991A (cg-RX-API-DMAC7.html)
WO (1) WO2022240886A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2812598A1 (en) * 2010-11-10 2012-05-18 Theravance, Inc. Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
BR112017026173A2 (pt) * 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo
FI3381896T3 (fi) * 2015-11-27 2023-04-21 Taiho Pharmaceutical Co Ltd Bifenyyliyhdiste tai sen suola
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs
MX2022005811A (es) * 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.

Also Published As

Publication number Publication date
CN117769540A (zh) 2024-03-26
JP2024518429A (ja) 2024-05-01
WO2022240886A1 (en) 2022-11-17
EP4337638A1 (en) 2024-03-20
US20240228438A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
TWI874490B (zh) 三苯化合物之新穎鹽類
JP6756617B2 (ja) N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
AU2020276695B2 (en) New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
JP2017505796A5 (cg-RX-API-DMAC7.html)
WO2007023182A1 (en) Delta and epsilon crystal forms of imatinib mesylate
US20240228438A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2- hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
WO2024248083A1 (ja) キノリン置換化合物の結晶
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
EP1960380A1 (en) F,g,h,i and k crystal forms of imatinib mesylate
CN104540822B (zh) 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2016155578A1 (zh) 达格列净的新晶型及其制备方法
US20210015817A1 (en) Solid-state forms of abemaciclib, their use and preparation
WO2018103027A1 (zh) 替吡法尼的晶型及其制备方法及药物组合物
CN104379581B (zh) 达拉菲尼的晶型及其制备方法和用途
JP2025541841A (ja) オキソイソインドール-5-カルボキサミド系化合物またはその塩、溶媒和物の結晶形または無定形
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
JP7618575B2 (ja) N-(5-((4-エチルピペラジン-1-イル)メチル)ピリジン-2-イル)-5-フルオロ-4-(3-イソプロピル-2-メチル-2h-インダゾール-5-イル)ピリミジン-2-アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
HK40108981A (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
JP7788550B2 (ja) ターフェニル化合物の安息香酸塩の製造方法
WO2026095022A1 (ja) キノリン置換化合物の結晶
KR20260074269A (ko) 아크릴아미드 화합물의 결정형 vi와 이의 제조 방법 및 용도
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
TW202542122A (zh) 包含(5r,6s)—10,11—二氟—12—((2—氟—4—碘苯基)—5,6—二羥基—4,5,6,7—四氫—111—螺[苯并[b][1,5,4]氧雜噻西啶—3,1'—環丙烷]2,2—二氧化物之固體形式以及包含其之組合物及使用其之方法
TW202543633A (zh) 喹唑啉酮衍生物的晶型及其製備方法和應用